logo

BCAB

Bioatla·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

BCAB fundamentals

Bioatla (BCAB) released its earnings on Nov 13, 2025: revenue was 0 (YoY -100.00%), beat estimates; EPS was -0.27 (YoY -22.73%), beat estimates.
Revenue / YoY
0
-100.00%
EPS / YoY
-0.27
-22.73%
Report date
Nov 13, 2025
BCAB Earnings Call Summary for Q3,2025
  • Strategic Momentum: Imminent Phase III trial initiation for Oz-V in OPSCC with $800M peak sales potential.
  • Clinical Success: BA3182 shows tumor control across 8 adenocarcinoma types; Mec-V OS doubles current standards.
  • Financial Resilience: $2M milestone payment offsets $15.8M net loss; R&D/G&A expenses down 69%/29%.
  • Upcoming Milestones: Oz-V interim analysis H2 2025; BA3182 data readout H1 2026.
EPS
Revenue

Revenue & Expenses

Key Indicators

Bioatla (BCAB) key financial stats and ratios, covering profitability, financial health, and leverage.
Bioatla (BCAB)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Bioatla (BCAB)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Bioatla (BCAB)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Bioatla (BCAB) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Bioatla (BCAB) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield